UCB, Eli Lilly-backed ViaNautis raises $25M in Series A to develop genetic nanomedicines
UK-based biotech ViaNautis Bio has bagged $25 million in a Series A round supported by two Big Pharma companies to advance its nanomedicine technology with an early focus on RNA-based treatments.
ViaNautis — previously known as SomaServe — was spun out of University College London in 2018. Its Series A round was jointly led by 4BIO Capital, BGF, and UCB Ventures. Other contributors included the Cystic Fibrosis Foundation and Eli Lilly, as well as existing investors Origin Capital, Meltwind and O2H.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.